Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melphalan drug delivery system - Delcath Systems

Drug Profile

Melphalan drug delivery system - Delcath Systems

Alternative Names: CHEMOSAT; CS-PHP-Melphalan; Generation Two CHEMOSAT Delivery System for Melphalan; Melblez Kit; Melphalan/HDS; Melphalan/Hepatic Delivery System

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University School of Medicine
  • Developer Delcath Systems
  • Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA damage stimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Neuroendocrine tumours; Cholangiocarcinoma; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Liver metastases
  • Phase II/III Cholangiocarcinoma
  • Phase II Liver cancer

Most Recent Events

  • 13 Feb 2019 Melphalan drug delivery system is available for licensing in Latin America, Brazil, as of 11 Feb 2019
  • 11 Feb 2019 Registered for Liver metastases (Inoperable/Unresectable) in Brazil (Intrahepatic)
  • 26 Dec 2018 Melphalan drug delivery system licensed to medac in European Union, Norway, Liechtenstein, Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top